CA2758883C - Stabilization of radiopharmaceutical compositions using ascorbic acid - Google Patents

Stabilization of radiopharmaceutical compositions using ascorbic acid Download PDF

Info

Publication number
CA2758883C
CA2758883C CA2758883A CA2758883A CA2758883C CA 2758883 C CA2758883 C CA 2758883C CA 2758883 A CA2758883 A CA 2758883A CA 2758883 A CA2758883 A CA 2758883A CA 2758883 C CA2758883 C CA 2758883C
Authority
CA
Canada
Prior art keywords
composition
ascorbic acid
radiopharmaceutical
solution
per milliliter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2758883A
Other languages
English (en)
French (fr)
Other versions
CA2758883A1 (en
Inventor
James F. Castner
Dianne D. Zdankiewicz
James E. Anderson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lantheus Medical Imaging Inc
Original Assignee
Lantheus Medical Imaging Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42983052&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2758883(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lantheus Medical Imaging Inc filed Critical Lantheus Medical Imaging Inc
Publication of CA2758883A1 publication Critical patent/CA2758883A1/en
Application granted granted Critical
Publication of CA2758883C publication Critical patent/CA2758883C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/0412—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K51/0421—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2758883A 2009-04-15 2010-04-15 Stabilization of radiopharmaceutical compositions using ascorbic acid Active CA2758883C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16935309P 2009-04-15 2009-04-15
US61/169,353 2009-04-15
PCT/US2010/001120 WO2010120368A2 (en) 2009-04-15 2010-04-15 Stabilization of radiopharmaceutical compositions using ascorbic acid

Publications (2)

Publication Number Publication Date
CA2758883A1 CA2758883A1 (en) 2010-10-21
CA2758883C true CA2758883C (en) 2020-03-10

Family

ID=42983052

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2758883A Active CA2758883C (en) 2009-04-15 2010-04-15 Stabilization of radiopharmaceutical compositions using ascorbic acid

Country Status (14)

Country Link
US (3) US9687571B2 (https=)
EP (1) EP2419096B1 (https=)
JP (1) JP5662416B2 (https=)
KR (2) KR20160030589A (https=)
CN (2) CN107261159B (https=)
AU (1) AU2016201367B2 (https=)
CA (1) CA2758883C (https=)
DK (1) DK2419096T3 (https=)
ES (1) ES2770364T3 (https=)
IL (1) IL215823A (https=)
LT (1) LT2419096T (https=)
PT (1) PT2419096T (https=)
WO (1) WO2010120368A2 (https=)
ZA (1) ZA201108351B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7344702B2 (en) 2004-02-13 2008-03-18 Bristol-Myers Squibb Pharma Company Contrast agents for myocardial perfusion imaging
ES2405655T3 (es) 2006-12-26 2013-05-31 Lantheus Medical Imaging, Inc. N-[3-bromo-4-(3-[18F]fluoropropoxi)-bencil]-guanidina para la formación de imágenes de la inervación cardíaca
WO2009108376A2 (en) 2008-02-29 2009-09-03 Lantheus Medical Imaging, Inc. Contrast agents for applications including perfusion imaging
KR20160030589A (ko) 2009-04-15 2016-03-18 랜티우스 메디컬 이메징, 인크. 아스코르브산을 사용한 방사성 약제 조성물의 안정화
DK3323810T3 (da) 2010-02-08 2022-03-28 Lantheus Medical Imaging Inc Automatiseret reaktionssystem, kassette og indretning til syntese af billeddannelsesmidler
ES2763815T3 (es) 2010-05-11 2020-06-01 Lantheus Medical Imaging Inc Composiciones, métodos y sistemas para la síntesis y uso de agentes de formación de imágenes
CN108484449A (zh) 2011-09-09 2018-09-04 蓝瑟斯医学影像公司 用于合成和使用显像剂的组合物、方法和系统
CA2852395C (en) * 2011-10-21 2020-04-28 Lantheus Medical Imaging, Inc. Compositions comprising ascorbic acid and pyridaben and pyridaben analogs attached to an imaging moiety and related methods
WO2013070471A1 (en) 2011-11-11 2013-05-16 Lantheus Medical Imaging, Inc. Evaluation of presence of and vulnerability to atrial fibrillation and other indications using matrix metalloproteinase-based imaging
PT2836241T (pt) * 2012-04-10 2019-05-30 Lantheus Medical Imaging Inc Métodos de síntese de radiofármacos
AU2013203000B9 (en) 2012-08-10 2017-02-02 Lantheus Medical Imaging, Inc. Compositions, methods, and systems for the synthesis and use of imaging agents
WO2016111797A1 (en) * 2015-01-09 2016-07-14 Immunomedics, Inc. Radiosensitivity of fluorophores and use of radioprotective agents for dual-modality imaging
WO2017014599A1 (ko) * 2015-07-22 2017-01-26 주식회사 씨코헬스케어 [18f]플루오로-도파의 방사화학적 순도를 안정화시키는 조성물 및 이의 제조방법
JP2019531706A (ja) * 2016-08-12 2019-11-07 インブイティ・インコーポレイテッドＩｎｖｕｉｔｙ， Ｉｎｃ． 術前および術中の組織の局在化および視覚化のための組織特異的マーカー
GB201805253D0 (en) * 2018-03-29 2018-05-16 Ge Healthcare Ltd Ip Solid phase extraction
WO2020202831A1 (ja) * 2019-03-29 2020-10-08 国立研究開発法人量子科学技術研究開発機構 放射性医薬の製造方法及び放射性医薬
GB201915206D0 (en) 2019-10-21 2019-12-04 Ge Healthcare Ltd Use of cyclodextrins as a radiostabilizer
KR102207372B1 (ko) * 2020-03-31 2021-01-27 재단법인 아산사회복지재단 방사성 의약품의 안정화제 및 이를 포함하는 방사성 의약 조성물
WO2022156907A1 (en) 2021-01-25 2022-07-28 Vrije Universiteit Brussel Method and kit for labeling a biomolecule with one or more detectable labels, including a radiolabel
GB202108608D0 (en) * 2021-06-16 2021-07-28 Ge Healthcare Ltd Preparation of a ph-adjusted ascorbic acid solution
CN114835690B (zh) * 2022-07-04 2022-09-27 北京先通国际医药科技股份有限公司 含化合物i的液体组合物的制备方法、及在心肌灌注pet显像中的用途
CN114832118B (zh) * 2022-07-04 2022-09-27 北京先通国际医药科技股份有限公司 化合物i液体组合物、制备方法及其用途
WO2024259346A1 (en) 2023-06-16 2024-12-19 Progenics Pharmaceuticals, Inc Improved synthesis of the prostate specific membrane antigen (psma) radiolabeled inhibitor [18f]dcfpyl

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1073999A (en) 1965-01-29 1967-06-28 Ncr Co Process for forming stable images in photochromic material
US4510125A (en) * 1982-12-08 1985-04-09 Mallinckrodt, Inc. Process for making lyophilized radiographic imaging kit
DE3574870D1 (de) 1984-06-23 1990-01-25 Nissan Chemical Ind Ltd Verfahren zu herstellung von 2-tert.-butyl-4,5-dichloro-3(2h)-pyridazinon.
US5393512A (en) 1985-01-14 1995-02-28 Vanderheyden; Jean-Luc Stable therapeutic radionuclide compositions and methods for preparation thereof
AU6621586A (en) 1985-11-18 1987-06-02 University Of Texas System, The Polychelating agents for image and spectral enhancement (and spectral shift)
JPS6315974A (ja) 1986-07-09 1988-01-23 小泉コンピユ−タ−株式会社 ボ−リングゲ−ム点数表表示装置
US5252317A (en) 1986-11-10 1993-10-12 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon Amplifier molecules for diagnosis and therapy derived from 3,5-bis[1-(3-amino-2,2-bis (aminomethyl)-propyl) oxymethyl] benzoic acid
US5567411A (en) 1986-11-10 1996-10-22 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon Dendritic amplifier molecules having multiple terminal active groups stemming from a benzyl core group
IT1229684B (it) 1989-04-05 1991-09-06 Mini Ricerca Scient Tecnolog Piridazinoni ad attivita' insetticida ed acaricida
US5087440A (en) 1989-07-31 1992-02-11 Salutar, Inc. Heterocyclic derivatives of DTPA used for magnetic resonance imaging
GB8923843D0 (en) 1989-10-23 1989-12-13 Salutar Inc Compounds
US5377681A (en) 1989-11-13 1995-01-03 University Of Florida Method of diagnosing impaired blood flow
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US5228446A (en) 1989-12-22 1993-07-20 Unger Evan C Gas filled liposomes and their use as ultrasonic contrast agents
US5088499A (en) 1989-12-22 1992-02-18 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5679810A (en) 1990-01-19 1997-10-21 Salutar, Inc. Linear oligomeric polychelant compounds
US5011676A (en) 1990-03-27 1991-04-30 Thomas Jefferson University Method to directly radiolabel antibodies for diagnostic imaging and therapy
WO1992017215A1 (en) 1990-03-28 1992-10-15 Nycomed Salutar, Inc. Contrast media
GB9006977D0 (en) 1990-03-28 1990-05-23 Nycomed As Compositions
US5205290A (en) 1991-04-05 1993-04-27 Unger Evan C Low density microspheres and their use as contrast agents for computed tomography
US5306482A (en) 1991-04-09 1994-04-26 Merck Frosst Canada, Inc. Radiopharmaceutical bacteriostats
US5093105A (en) 1991-04-09 1992-03-03 Merck Frosst Canada, Inc. Radiopharmaceutical bacteriostats
DK0600992T3 (da) 1991-08-29 2000-10-09 Mallinckrodt Medical Inc Anvendelse af gentissyre eller gentisylalkohol til stabilisering af radiomærkede peptider og proteiner
US5169942A (en) 1991-11-21 1992-12-08 General Electric Company Method for making 2-(18F)fluoro-2-deoxy-D-glucose
US5760191A (en) 1993-02-05 1998-06-02 Nycomed Imaging As Macrocyclic complexing agents and targeting immunoreagents useful in therapeutic and diagnostic compositions and methods
JPH07507813A (ja) 1993-03-22 1995-08-31 ゼネラル・エレクトリック・カンパニイ ２−フルオロ−２−デオキシグルコースの製造方法
CA2158249A1 (en) 1993-03-31 1994-10-13 James W. Brodack Radiopharmaceutical formulations having non-stannous reductants
US5417959A (en) 1993-10-04 1995-05-23 Mallinckrodt Medical, Inc. Functionalized aza-crytand ligands for diagnostic imaging applications
BR9408590A (pt) 1994-06-03 1997-08-26 Malinckrodt Medical Inc Agentes para imageamento ósseo rapidamente eliminaveis de fosfonato de tecnécio 99m
US5520904A (en) 1995-01-27 1996-05-28 Mallinckrodt Medical, Inc. Calcium/oxyanion-containing particles with a polymerical alkoxy coating for use in medical diagnostic imaging
EP0727225A3 (en) 1995-02-14 1997-01-15 Sonus Pharma Inc Compositions and methods for directed ultrasonic imaging
US5587491A (en) 1995-03-15 1996-12-24 Regents Of The University Of Minnesota Method for the synthesis of bis-tetrahydrofuranyl Annonaceous acetogenins
US5801228A (en) 1995-06-07 1998-09-01 Nycomed Imaging As Polymeric contrast agents for medical imaging
US6066309A (en) 1996-02-02 2000-05-23 Rhomed Incorporated Post-labeling stabilization of radiolabeled proteins and peptides
US5804161A (en) 1996-05-14 1998-09-08 Nycomed Salutar Inc. Contrast agents
US5846517A (en) 1996-09-11 1998-12-08 Imarx Pharmaceutical Corp. Methods for diagnostic imaging using a renal contrast agent and a vasodilator
US6027710A (en) * 1996-09-18 2000-02-22 Nihon Medi-Physiscs Co., Ltd. Radiation-protecting agent
US6565889B2 (en) 1996-12-02 2003-05-20 The Regents Of The University Of California Bilayer structure which encapsulates multiple containment units and uses thereof
US5961955A (en) 1997-06-03 1999-10-05 Coulter Pharmaceutical, Inc. Radioprotectant for peptides labeled with radioisotope
US7060251B1 (en) * 1997-09-08 2006-06-13 The General Hospital Corporation Imaging agents for early detection and monitoring of cardiovascular plaque
US6056939A (en) 1998-08-28 2000-05-02 Desreux; Jean F. Self-assembling heteropolymetallic chelates as imaging agents and radiopharmaceuticals
EP1119356B1 (en) 1998-09-29 2009-08-19 Merck & Co., Inc. Radiolabeled neurokinin-1 receptor antagonists
US6645508B1 (en) * 1999-06-18 2003-11-11 Jivn-Ren Chen Stable L-ascorbic acid composition
WO2002020008A1 (en) 2000-09-06 2002-03-14 The Scripps Research Institute Inhibitors of nadh:ubiquinone oxidoreductase
TWI247609B (en) 2001-01-23 2006-01-21 Nihon Mediphysics Co Ltd Agent for diagnosis of tissue proliferation activity or the treatment of proliferative disease
CZ20032597A3 (cs) 2001-02-26 2004-12-15 Bristol-Myers Squibb Pharma Company Analogy kyseliny askorbové pro metaloradiofarmaceutika
GB0115927D0 (en) 2001-06-29 2001-08-22 Nycomed Amersham Plc Solid-phase nucleophilic fluorination
US7344702B2 (en) * 2004-02-13 2008-03-18 Bristol-Myers Squibb Pharma Company Contrast agents for myocardial perfusion imaging
US20030044354A1 (en) 2001-08-16 2003-03-06 Carpenter Alan P. Gas microsphere liposome composites for ultrasound imaging and ultrasound stimulated drug release
WO2003032912A2 (en) 2001-10-16 2003-04-24 Hypnion, Inc. Treatment of cns disorders using cns target modulators
EP1474177A4 (en) 2002-02-06 2010-07-21 Univ Johns Hopkins NONINVASIVE DIAGNOSTIC IMAGING TECHNOLOGY FOR MITOCHONDRIA USING LIPOPHILER SALTS
CA2479109C (en) 2002-03-29 2011-08-02 Janssen Pharmaceutica N.V. Radiolabelled quinoline and quinolinone derivatives and their use as metabotropic glutamate receptor ligands
AU2003224747A1 (en) 2002-04-08 2003-10-27 Biostream, Inc. Technetium-labeled rotenone derivatives, and methods of use thereof
EP1356827A1 (en) 2002-04-24 2003-10-29 Mallinckrodt Inc. Method for obtaining a 2-18F-fluor-2-deoxy-D-glucose (18F-FDG)-solution
GB0229683D0 (en) 2002-12-20 2003-01-29 Imaging Res Solutions Ltd Preparation of radiopharmaceuticals
JP5139678B2 (ja) 2003-07-24 2013-02-06 ブラッコ・イメージング・ソシエタ・ペル・アチオニ 安定な放射性医薬品組成物およびその製法
GB0317920D0 (en) 2003-07-31 2003-09-03 Amersham Plc Solid-phase synthesis
US7485283B2 (en) 2004-04-28 2009-02-03 Lantheus Medical Imaging Contrast agents for myocardial perfusion imaging
US20060083681A1 (en) 2004-10-18 2006-04-20 Ajay Purohit Compounds for myocardial perfusion imaging
KR100789847B1 (ko) 2004-12-15 2007-12-28 (주)퓨쳐켐 알코올 용매하에서 유기플루오로 화합물의 제조방법
AU2006262502A1 (en) 2005-06-23 2007-01-04 Emory Univerisity Imaging agents
GB0514087D0 (en) 2005-07-11 2005-08-17 Ge Healthcare Ltd Stabilised radiopharmaceutical compositions
US7824659B2 (en) 2005-08-10 2010-11-02 Lantheus Medical Imaging, Inc. Methods of making radiolabeled tracers and precursors thereof
CA2654369C (en) 2006-06-21 2014-10-14 Ge Healthcare Limited Radiopharmaceutical products
US8889100B2 (en) * 2007-01-11 2014-11-18 Immunomedics, Inc. Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules
JP5258583B2 (ja) 2007-02-13 2013-08-07 日本メジフィジックス株式会社 放射性画像診断剤の製造方法
GB0718386D0 (en) 2007-09-21 2007-10-31 Ge Healthcare As Improved radiopharmaceutical formulation
WO2009108376A2 (en) 2008-02-29 2009-09-03 Lantheus Medical Imaging, Inc. Contrast agents for applications including perfusion imaging
KR20160030589A (ko) 2009-04-15 2016-03-18 랜티우스 메디컬 이메징, 인크. 아스코르브산을 사용한 방사성 약제 조성물의 안정화
CN101555232B (zh) 2009-05-21 2011-01-05 北京师范大学 氟-18标记哒嗪酮类化合物及制备方法和应用
DK3323810T3 (da) 2010-02-08 2022-03-28 Lantheus Medical Imaging Inc Automatiseret reaktionssystem, kassette og indretning til syntese af billeddannelsesmidler
ES2763815T3 (es) 2010-05-11 2020-06-01 Lantheus Medical Imaging Inc Composiciones, métodos y sistemas para la síntesis y uso de agentes de formación de imágenes
CN108484449A (zh) 2011-09-09 2018-09-04 蓝瑟斯医学影像公司 用于合成和使用显像剂的组合物、方法和系统
CA2852395C (en) 2011-10-21 2020-04-28 Lantheus Medical Imaging, Inc. Compositions comprising ascorbic acid and pyridaben and pyridaben analogs attached to an imaging moiety and related methods

Also Published As

Publication number Publication date
EP2419096B1 (en) 2019-11-13
US20180071411A1 (en) 2018-03-15
CN102458396B (zh) 2017-05-10
CN102458396A (zh) 2012-05-16
ZA201108351B (en) 2019-03-27
KR101602992B1 (ko) 2016-03-11
US20130101508A9 (en) 2013-04-25
DK2419096T3 (da) 2020-02-03
IL215823A0 (en) 2012-01-31
EP2419096A4 (en) 2015-06-03
WO2010120368A3 (en) 2011-02-24
KR20120017427A (ko) 2012-02-28
AU2010237040A1 (en) 2011-12-08
ES2770364T3 (es) 2020-07-01
AU2010237040B2 (en) 2015-12-03
CN107261159A (zh) 2017-10-20
AU2016201367B2 (en) 2017-11-23
KR20160030589A (ko) 2016-03-18
CA2758883A1 (en) 2010-10-21
PT2419096T (pt) 2020-02-19
LT2419096T (lt) 2020-04-10
CN107261159B (zh) 2021-01-12
EP2419096A2 (en) 2012-02-22
US20120237445A1 (en) 2012-09-20
JP5662416B2 (ja) 2015-01-28
IL215823A (en) 2015-10-29
US20200222562A1 (en) 2020-07-16
US9687571B2 (en) 2017-06-27
HK1245645A1 (zh) 2018-08-31
JP2012524064A (ja) 2012-10-11
AU2016201367A1 (en) 2016-03-24
WO2010120368A2 (en) 2010-10-21

Similar Documents

Publication Publication Date Title
CA2758883C (en) Stabilization of radiopharmaceutical compositions using ascorbic acid
KR101485445B1 (ko) 방사성 화상진단제의 제조 방법
SG172439A1 (en) Synthesis of 18f-radiolabeled styrylpyridines from tosylate precursors and stable pharmaceutical compositions thereof
JP2023552180A5 (https=)
JP5159636B2 (ja) 放射性画像診断剤
Ametamey et al. Fluorine-18 radiolabelling, biodistribution studies and preliminary PET evaluation of a new memantine derivative for imaging the NMDA receptor
JP2026050460A (ja) ６４Ｃｕ－ＤＯＴＡＴＡＴＥのスケールアップのための放射標識および製剤化
TWI905175B (zh) 放射性標記psma結合配位體的方法及其套組
Loc'h et al. Preparation of [76Br] FLB 457 and [76Br] FLB 463 for examination of striatal and extrastriatal dopamine D-2 receptors with PET
AU2010237040B9 (en) Stabilization of radiopharmaceutical compositions using ascorbic acid
US20240024519A1 (en) Radiopharmaceutical compositions of copper for targeted molecular imaging
HK1167344B (en) Stabilization of radiopharmaceutical compositions using ascorbic acid
HK1167344A (en) Stabilization of radiopharmaceutical compositions using ascorbic acid
HK1245645B (zh) 使用抗坏血酸稳定化放射性药物组合物
HK1170672A (en) Stabilization of radiopharmaceutical compositions using ascorbic acid
HK1170672B (en) Stabilization of radiopharmaceutical compositions using ascorbic acid
EP1846043B1 (en) Bridgehead radiolabelled compounds and methods of using the same

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150414

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 15TH ANNIV.) - STANDARD

Year of fee payment: 15

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250407

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250407